Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06251102
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-09
First Post:
2024-02-01
Brief Title:
Real-world Ruxolitinib Experience in PV
Sponsor:
Gruppo Italiano Malattie EMatologiche dellAdulto
Organization:
Gruppo Italiano Malattie EMatologiche dellAdulto
Study Overview
Official Title:
Real-world Ruxolitinib Experience in Polycythemia Vera REVIEW Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REVIEW
Brief Summary:
This is a multicentric observational retro-prospective study in adult PV patients - resistant or intolerant to hydroxyurea - who are going to receive or have already initiated treatment with ruxolitinib according to the approved local label Enrolment will last 9 months after the first enrolled patient Patients will be observed for a minimum of 3 months in order to evaluate the primary endpoint for all patients
Detailed Description:
This is a multicentric observational retro-prospective study in adult population who have been diagnosed with polycythemia vera according to the 2022 WHO or ICC criteria who are resistant or intolerant to hydroxyurea and who are going to be prescribed or have already initiated treatment with ruxolitinib according to the approved local label Patients who started treatment with ruxolitinib - according to clinical practice - will be enrolled Enrolment will last 9 months after the first enrolled patient Patients will be observed for a minimum of 3 months in order to evaluate the primary endpoint for all patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None